Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Pfizer announced on Monday that it’s halting the development of its weight loss pill Danuglipron after a trial patient suffered a liver injury. According to a press […] ...

The announcement adds to a string of setbacks in Pfizer’s bid to win a slice of the booming market that Wall Street projects ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer has ended development of danuglipron, an oral GLP-1 drug for weight management, citing clinical data and regulatory input.

Pfizer (PFE) announced the decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was ...

Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.